AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Back-up contraception no longer required with Norplant.(Brief Article)
2002 SEP 5 - (NewsRx.com & NewsRx.net) -- Wyeth Pharmaceuticals, a division of Wyeth (WYE), is announcing that users of its Norplant System (levonorgestrel implants) no longer need a back-up, barrier, or other nonhormonal method of contraception such as condoms, spermicides, diaphragms, or IUDs.
This development is the result of several product tests of Norplant conducted by the company that have not suggested lower contraceptive effectiveness than that reported in clinical trials and the product labeling.
This is an update to the August 10, 2000, and September 13, 2000, letters that advised healthcare professionals to discontinue insertion of Norplant kits from lots distributed beginning October 20, 1999, ...
- FDA approves use of Zosyn in a more convenient regimen, new low dose estrogen.
- Newspaper article from: OBGYN & Reproduction Week May 26, 2003 700+ words
...sets will be eliminated," says Victoria Kusiak, MD, VP, Global Medical Affairs and North American Medical director...particularly for new patients," says Victoria Kusiak, VP Global Medical Affairs, and North American Medical director...
- Wyeth's New Low Dose Estrogen Tablets Approved for Prevention Of Postmenopausal...
- Press release article from: PR Newswire July 17, 2003 700+ words
...individualize effective treatment for menopausal symptom relief and concomitant bone protection," says Victoria Kusiak, Vice President Global Medical Affairs, and North American Medical Director, Wyeth Pharmaceuticals. Data supporting the efficacy...
- FDA Approves a New Wyeth Low Dose Estrogen Therapy Product; Approval Will...
- Press release article from: PR Newswire April 25, 2003 700+ words
...will facilitate better individualization of therapy, particularly for new patients," says Victoria Kusiak, Vice President Global Medical Affairs, and North American Medical Director, Wyeth Pharmaceuticals. The FDA, other health experts...
- FDA Approves New Strength of Wyeth Low Dose Hormone Therapy; Agency Also...
- Press release article from: PR Newswire June 9, 2003 700+ words
...individualize effective treatment for menopausal symptom relief and concomitant bone protection," says Victoria Kusiak, Vice President Global Medical Affairs, and North American Medical Director, Wyeth Pharmaceuticals. Data supporting the efficacy...
- Ten Thousand Patients Enrolled in Landmark Rheumatoid Arthritis Study Program;...
- Press release article from: PR Newswire July 9, 2003 700+ words
...Jonathan Leff, Amgen's senior director of medical affairs. "This study is expected to enrich the...physicians in patients with RA," said Dr. Victoria Kusiak, vice president of global medical affairs and North American medical director of...
- HERS II finds HRT has neutral effect on preexisting heart disease.
- Newspaper article from: Heart Disease Weekly August 25, 2002 700+ words
...community and the public already know about HRT and the treatment of heart disease," said Victoria Kusiak, MD, vice president, global medical affairs and North American medical director for Wyeth Pharmaceuticals, the study's sponsor...
- NIH paper reveals faltering faith in HRT as panacea: HRT for heart, fractures...
- Magazine article from: OB GYN News Demott, Kathryn June 1, 2002 700+ words
...alternatives to HRT that have been proven to be more effective and safer for targeted uses. Dr. Victoria Kusiak, vice president of global medical affairs and North American medical director at Wyeth Pharmaceuticals, emphasized in an interview that...
- FDA Approves Wyeth's New Low Dose Prempro(TM) Lower Hormone Dose With Efficacy...
- Press release article from: PR Newswire March 13, 2003 700+ words
...dose Prempro is an important new option for the treatment of menopausal symptoms," says Dr. Victoria Kusiak, Vice President of Global Medical Affairs and North American Medical Director for Wyeth Pharmaceuticals. "If symptoms are an issue...